Pheochromocytoma natural history, complications and prognosis

Revision as of 19:16, 2 September 2015 by Ahmad Al Maradni (talk | contribs)
Jump to navigation Jump to search

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma natural history, complications and prognosis

CDC on Pheochromocytoma natural history, complications and prognosis

Pheochromocytoma natural history, complications and prognosis in the news

Blogs on Pheochromocytoma natural history, complications and prognosis

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Prognosis of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5 year survival rate of approximately 45%.[1] Massive release of catecholamines can causes damage to myocytes.

Complication

The massive release of catecholamines in pheochromocytoma can cause damage to myocytes.[2] This damage may be due to either compromising the coronary microcirculation or by direct toxic effects on the myocytes.[2] Other complication may include:

Prognosis

The 5-year survival in the setting of metastatic disease (whether identified at the time of initial diagnosis or identified postoperatively as recurrent disease) is 40% to 45%

References

  1. National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
  2. 2.0 2.1 Goldman 2011, pp. 327

Template:WikiDoc Sources